Bernard  Coulie net worth and biography

Bernard Coulie Biography and Net Worth

Pliant CEO Bernard Coulie, M.D., Ph.D., brings to the company more than 15 years of senior leadership experience and drug development expertise. He joined Pliant from ActoGeniX (acquired by Intrexon Corporation in February 2015), where he was CEO, Chief Medical Officer and Co-Founder. In these positions, Dr. Coulie played an integral role in advancing the company’s unique technology platform for oral delivery of biologics from early discovery stage through Phase 2 studies. Prior to ActoGeniX, Dr. Coulie held various positions with increasing responsibilities in drug discovery and clinical development at Johnson & Johnson Pharmaceutical Research and Development Europe. At Johnson & Johnson, he served as Therapeutic Area Leader Internal Medicine, managing a portfolio of products in GI, metabolic diseases and inflammation/immunology, ranging from early drug discovery through Phase 2 studies. Earlier in his career, Dr. Coulie was a Staff Physician in the Department of Gastroenterology and Hepatology at Mayo Clinic (Rochester, MN), Assistant Professor in Medicine at Mayo Medical School and a Mayo Foundation scholar. Dr. Coulie serves as the Independent Chairman of the Board of Directors at Calypso Biotech, a privately-held biotechnology company based in the Netherlands and is a member of the Board of Directors of SQZ Biotechnologies, a publicly-traded cell therapy biotechnology company.

Dr. Coulie holds an M.D. and Ph.D. from the University of Leuven, Belgium. He is a board-certified internist and holds an MBA from the Vlerick Management School, Leuven, Belgium.

What is Bernard Coulie's net worth?

The estimated net worth of Bernard Coulie is at least $4.88 million as of July 17th, 2023. Dr. Coulie owns 342,103 shares of Pliant Therapeutics stock worth more than $4,878,389 as of December 6th. This net worth evaluation does not reflect any other investments that Dr. Coulie may own. Additionally, Dr. Coulie receives a salary of $1,060,000.00 as CEO at Pliant Therapeutics. Learn More about Bernard Coulie's net worth.

How old is Bernard Coulie?

Dr. Coulie is currently 57 years old. There are 4 older executives and no younger executives at Pliant Therapeutics. Learn More on Bernard Coulie's age.

What is Bernard Coulie's salary?

As the CEO of Pliant Therapeutics, Inc., Dr. Coulie earns $1,060,000.00 per year. Learn More on Bernard Coulie's salary.

How do I contact Bernard Coulie?

The corporate mailing address for Dr. Coulie and other Pliant Therapeutics executives is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. Pliant Therapeutics can also be reached via phone at 650-481-6770 and via email at [email protected]. Learn More on Bernard Coulie's contact information.

Has Bernard Coulie been buying or selling shares of Pliant Therapeutics?

Bernard Coulie has not been actively trading shares of Pliant Therapeutics over the course of the past ninety days. Most recently, Bernard Coulie sold 70,150 shares of the business's stock in a transaction on Monday, July 17th. The shares were sold at an average price of $18.01, for a transaction totalling $1,263,401.50. Following the completion of the sale, the chief executive officer now directly owns 342,103 shares of the company's stock, valued at $6,161,275.03. Learn More on Bernard Coulie's trading history.

Who are Pliant Therapeutics' active insiders?

Pliant Therapeutics' insider roster includes Bernard Coulie (CEO), and Eric Lefebvre (Insider). Learn More on Pliant Therapeutics' active insiders.

Are insiders buying or selling shares of Pliant Therapeutics?

In the last year, insiders at the sold shares 26 times. They sold a total of 482,028 shares worth more than $12,248,020.38. The most recent insider tranaction occured on August, 3rd when insider Hans Hull sold 13,069 shares worth more than $261,380.00. Insiders at Pliant Therapeutics own 5.6% of the company. Learn More about insider trades at Pliant Therapeutics.

Information on this page was last updated on 8/3/2023.

Bernard Coulie Insider Trading History at Pliant Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/17/2023Sell70,150$18.01$1,263,401.50342,103View SEC Filing Icon  
3/30/2023Sell35,339$26.52$937,190.28274,753View SEC Filing Icon  
2/3/2023Sell15,000$33.61$504,150.00240,112View SEC Filing Icon  
1/31/2023Sell15,000$34.92$523,800.00240,112View SEC Filing Icon  
1/26/2023Sell15,000$35.29$529,350.00240,112View SEC Filing Icon  
1/24/2023Sell15,000$30.89$463,350.0093,812View SEC Filing Icon  
1/9/2023Sell5,000$19.17$95,850.0093,812View SEC Filing Icon  
1/6/2023Sell15,000$19.04$285,600.0093,812View SEC Filing Icon  
1/3/2023Sell15,000$19.33$289,950.0093,812View SEC Filing Icon  
12/20/2022Sell34,212$19.10$653,449.2093,812View SEC Filing Icon  
9/12/2022Sell12,502$22.54$281,795.0859,273View SEC Filing Icon  
7/11/2022Sell15,000$22.50$337,500.0059,273View SEC Filing Icon  
6/14/2021Sell4,000$33.03$132,120.0054,840View SEC Filing Icon  
5/14/2021Sell3,500$28.64$100,240.0054,840View SEC Filing Icon  
4/14/2021Sell3,500$30.33$106,155.0054,840View SEC Filing Icon  
3/15/2021Sell3,500$38.52$134,820.0048,840View SEC Filing Icon  
1/14/2021Sell3,500$26.38$92,330.0048,840View SEC Filing Icon  
12/14/2020Sell3,500$27.37$95,795.0048,840View SEC Filing Icon  
See Full Table

Bernard Coulie Buying and Selling Activity at Pliant Therapeutics

This chart shows Bernard Coulie's buying and selling at Pliant Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pliant Therapeutics Company Overview

Pliant Therapeutics logo
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase IIa trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis. It also develops PLN-1474, a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Read More

Today's Range

Now: $14.26
Low: $14.07
High: $14.72

50 Day Range

MA: $14.83
Low: $12.85
High: $17.61

2 Week Range

Now: $14.26
Low: $12.60
High: $36.64


142,227 shs

Average Volume

741,340 shs

Market Capitalization

$854.12 million

P/E Ratio


Dividend Yield